Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Rachida Lebtahi et al.|New England Journal of Medicine|2017Cited by 3.2k
Gastroenteropancreatic neuroendocrine tumoursIrvin M. Modlin, Anders Sundin, Kjell Öberg et al.|The Lancet Oncology|2008Cited by 1.8k
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsM. Caplin, Zeng Zheng-Pei, Éric Baudin et al.|Annals of Oncology|2015Cited by 698
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward M. Wolin, Beth Chasen et al.|Journal of Clinical Oncology|2018Cited by 388
Well-Differentiated Gastric Tumors/CarcinomasPhilippe Ruszniewski, Guido Rindi, Gianfranco Delle Fave et al.|Neuroendocrinology|2006Cited by 154